TY  - JOUR
AU  - Bandres-Ciga, Sara
AU  - Faghri, Faraz
AU  - Majounie, Elisa
AU  - Koretsky, Mathew J
AU  - Kim, Jeffrey
AU  - Levine, Kristin S
AU  - Leonard, Hampton
AU  - Makarious, Mary B
AU  - Iwaki, Hirotaka
AU  - Crea, Peter Wild
AU  - Hernandez, Dena G
AU  - Arepalli, Sampath
AU  - Billingsley, Kimberley
AU  - Lohmann, Katja
AU  - Klein, Christine
AU  - Lubbe, Steven J
AU  - Jabbari, Edwin
AU  - Saffie-Awad, Paula
AU  - Narendra, Derek
AU  - Reyes-Palomares, Armando
AU  - Quinn, John P
AU  - Schulte, Claudia
AU  - Morris, Huw R
AU  - Traynor, Bryan J
AU  - Scholz, Sonja W
AU  - Houlden, Henry
AU  - Hardy, John
AU  - Dumanis, Sonya
AU  - Riley, Ekemini
AU  - Blauwendraat, Cornelis
AU  - Singleton, Andrew
AU  - Nalls, Mike
AU  - Jeff, Janina
AU  - Vitale, Dan
TI  - NeuroBooster Array: A Genome-Wide Genotyping Platform to Study Neurological Disorders Across Diverse Populations.
JO  - Movement disorders
VL  - 39
IS  - 11
SN  - 0885-3185
CY  - New York, NY
PB  - Wiley
M1  - DZNE-2024-01333
SP  - 2039 - 2048
PY  - 2024
AB  - Commercial genome-wide genotyping arrays have historically neglected coverage of genetic variation across populations.We aimed to create a multi-ancestry genome-wide array that would include a wide range of neuro-specific genetic content to facilitate genetic research in neurological disorders across multiple ancestral groups, fostering diversity and inclusivity in research studies.We developed the Illumina NeuroBooster Array (NBA), a custom high-throughput and cost-effective platform on a backbone of 1,914,934 variants from the Infinium Global Diversity Array and added custom content comprising 95,273 variants associated with more than 70 neurological conditions or traits, and we further tested its performance on more than 2000 patient samples. This novel platform includes approximately 10,000 tagging variants to facilitate imputation and analyses of neurodegenerative disease-related genome-wide association study loci across diverse populations.In this article, we describe NBA's potential as an efficient means for researchers to assess known and novel disease genetic associations in a multi-ancestry framework. The NBA can identify rare genetic variants and accurately impute more than 15 million common variants across populations. Apart from enabling sample prioritization for further whole-genome sequencing studies, we envisage that NBA will play a pivotal role in recruitment for interventional studies in the precision medicine space.From a broader perspective, the NBA serves as a promising means to foster collaborative research endeavors in the field of neurological disorders worldwide. Ultimately, this carefully designed tool is poised to make a substantial contribution to uncovering the genetic etiology underlying these debilitating conditions. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.
KW  - Humans
KW  - Genome-Wide Association Study: methods
KW  - Nervous System Diseases: genetics
KW  - Genotype
KW  - Genetic Variation: genetics
KW  - Genotyping Techniques: methods
KW  - Polymorphism, Single Nucleotide: genetics
KW  - Genetic Predisposition to Disease: genetics
KW  - Centre for Alzheimer's and Related Dementias (Other)
KW  - Global Parkinson's Genetics Program (Other)
KW  - NeuroBooster array (Other)
KW  - diversity (Other)
KW  - genetic screening (Other)
KW  - genotyping (Other)
KW  - neurological diseases (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:39283294
C2  - pmc:PMC11568947
DO  - DOI:10.1002/mds.29902
UR  - https://pub.dzne.de/record/272954
ER  -